8/468145

```
Trying 11180...Open

PLEASE ENTER HOST PORT ID:
PLEASE ENTER HOST PORT ID:x
LOGINID:d18dnmm
PASSWORD:
TERMINAL (ENTER 1, 2, 3, 4, OR ?):□3

* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
*                                                                     *
*           Welcome to MESSENGER (APS Text) at USPTO                  *
*                                                                     *
*                                                                     *
*    The USPTO production files are current through:                  *
*    MARCH 16,1999  for U.S. Patent Text Data.                        *
*    MARCH 16,1999  for U.S. Current Classification Data.             *
*    MARCH 16,1999  for U.S. Patent Image Data.                       *
*                                                                     *
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
   AFTER PRODUCTION HOURS (AT 10:00 P.M.) ON WEDNESDAY, 01/27/99,
   SEVERAL PTONET DEVICES WILL BE RECONFIGURED TO ENHANCE
   NETWORK OPERATIONS.  USERS OF PATENT EXAMINER SEARCH TOOLS
   MUST RE-BOOT THEIR INDIVIDUAL DESKTOP WORKSTATIONS AT THE
   START OF THE BUSINESS DAY ON THURSDAY, 01/28/99 TO INSURE
   THAT NECESSARY FILES ON THEIR WORKSTATION GET UPDATED.  THIS
   WILL ENSURE IMMEDIATE AND ACCURATE ACCESS TO ALL OF THE
   PATENT EXAMINER SEARCH TOOLS.  THANK YOU FOR YOUR COOPERATION
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
*       * PLEASE USE 305-9000 FOR NEW TELEPHONE NUMBER *             *
*                                                                     *
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
* More U.S. patent data is now available on APS.  The new            *
* USOCR file contains patents issued in 1970, plus some              *
* patents that were missing from the USPAT file.  See the            *
* Patents News Folder under the Public Folders in e-mail for         *
* more information on using the new file.  Thank you.                *
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
*  DISCLAIMER:                                                        *
*  Neither the United States Government, nor any agency              *
*  thereof, nor any of their contractors, subcontractors or          *
*  employees make any warranty, expressed or implied,                *
*  including any warranty of marketability of fitness for a          *
*  particular purpose; nor assumes any legal liability or            *
*  responsibility for any party's use, or the results of             *
*  such, of the data.                                                *
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
*                Help Desk --> 703-305-9000                           *
*                                                                     *
*    The Help Desk is staffed for APS support 7 days/week.            *
*      Monday through Friday:       6:30am - 9:00pm                  *
*      Saturday, Sunday, Holidays: 8:30am - 5:00 pm                  *
*                                                                     *
*    The Help Desk staff at this number will handle all APS           *
*    related questions.                                               *
* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
*    >>>>>>>>>>>>> NEW SUNDAY HOURS !!! <<<<<<<<<<<<<                 *
*                                                                     *
*    The APS is available:                                            *
```

```
  *            6:30am - 9:00pm Monday through Friday              *
  *            7:30am - 5:00pm Saturday, Sunday, Holidays         *
  *                                                               *
  *      APS is unavailable Thanksgiving Day, Christmas Day,      *
  *      and New Year's Day.                                      *
  *                                                               *
  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
FILE 'USPAT' ENTERED AT 12:06:59 ON 18 MAR 1999

  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *
  *              W E L C O M E   T O   T H E                      *
  *         U. S.   P A T E N T   T E X T   F I L E               *
  * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *

=> e engel, jurgen/in

E#      FILE            FREQUENCY  TERM
--      ----            ---------  ----
E1      USPAT                 1     ENGEL, JOSEPH R/IN
E2      USPAT                 1     ENGEL, JUERGEN/IN
E3      USPAT                62 --> ENGEL, JURGEN/IN
E4      USPAT                 2     ENGEL, KARL/IN
E5      USPAT                 1     ENGEL, KARSTEN/IN
E6      USPAT                 4     ENGEL, KLAUS/IN
E7      USPAT                 1     ENGEL, KLAUS EBERHARD/IN
E8      USPAT                 2     ENGEL, KLAUS G/IN
E9      USPAT                13     ENGEL, KURT/IN
E10     USPAT                 2     ENGEL, L DAVID/IN
E11     USPAT                 3     ENGEL, LARRY J/IN
E12     USPAT                 1     ENGEL, LAURENCE G/IN

=> s e3

L1          62 "ENGEL, JURGEN"/IN

=> s l1 and lyophilisate

          580 LYOPHILISATE
L2          1 L1 AND LYOPHILISATE

=> d bib ab


US PAT NO:      5,663,145 [IMAGE AVAILABLE]              L2: 1 of 1
DATE ISSUED:    Sep. 2, 1997
TITLE:          Products for administering an initial high dose of
                  Cetrorelix and producing a combination package for use
                  when treating diseases
INVENTOR:       Jurgen Engel, Alzenau, Federal Republic of Germany
                Peter Hilgard, Frankfurt, Federal Republic of Germany
                Thomas Reissmann, Frankfurt, Federal Republic of Germany
ASSIGNEE:       ASTA Medica Aktiengesellschaft, Dresden, Federal Republic
                  of Germany (foreign corp.)
APPL-NO:        08/354,838
DATE FILED:     Dec. 8, 1994
ART-UNIT:       181
PRIM-EXMR:      Jeffrey E. Russel
LEGAL-REP:      Cushman Darby & Cushman IP Group of Pillsbury Madison &
                  Sutro LLP

US PAT NO:      5,663,145 [IMAGE AVAILABLE]              L2: 1 of 1

ABSTRACT:
For application during the treatment of benign and malign tumour
```

diseases, the product according to the invention containing the initial dose of Cetrorelix acetate and one or more maintenance doses of Cetrorelix acetate, Cetrorelix embonate or a slow-release form of Cetrorelix, is used as a combination preparation for treatment to be administered at specific time intervals.

```
=> e wichert, burkhard/in

E#      FILE            FREQUENCY  TERM
--      ----            ---------  ----
E1      USPAT                1     WICHERT, BERND/IN
E2      USPAT                1     WICHERT, BERNHARD/IN
E3      USPAT                2 --> WICHERT, BURKHARD/IN
E4      USPAT                1     WICHERT, GERHARD/IN
E5      USPAT                2     WICHERT, HANS/IN
E6      USPAT                1     WICHERT, MANFRED/IN
E7      USPAT                2     WICHERT, VOLKER/IN
E8      USPAT                2     WICHERT, WOLFGANG/IN
E9      USPAT                1     WICHETA, WILLIAM E/IN
E10     USPAT                1     WICHINSKY, LOUIS/IN
E11     USPAT                8     WICHINSKY, MICHAEL/IN
E12     USPAT                2     WICHINSKY, MICHAEL A/IN

=> s e3

L3            2 "WICHERT, BURKHARD"/IN

=> d cit 1-


1.  5,750,131, May 12, 1998, Ifosfamide lyophilizate preparations;
**Burkhard Wichert**, et al., 424/422, 423; 514/54, 57, 59, 60, 110
[IMAGE AVAILABLE]

2.  5,446,033, Aug. 29, 1995, Stabilized hexadecylphosphocholine
solutions in glycerol alkyl ethers; Jurgen Engel, et al., 514/77, 723,
769, 784 [IMAGE AVAILABLE]

=> d bib ab 1-


US PAT NO:      5,750,131 [IMAGE AVAILABLE]              L3: 1 of 2
DATE ISSUED:    May 12, 1998
TITLE:          Ifosfamide lyophilizate preparations
INVENTOR:       Burkhard Wichert, Bielefeld, Federal Republic of
                  Germany
                Dieter Sauerbier, Oerlinghausen, Federal Republic of
                  Germany
                Jurgen Rawert, Werther, Federal Republic of Germany
ASSIGNEE:       Asta Medica Aktiengesellschaft, Dresden, Federal Republic
                  of Germany (foreign corp.)
APPL-NO:        08/752,069
DATE FILED:     Nov. 19, 1996
ART-UNIT:       121
PRIM-EXMR:      Joseph McKane
LEGAL-REP:      Cushman Darby & Cushman IP Group Of Pillsbury Madison &
                  Sutro, LLP

US PAT NO:      5,750,131 [IMAGE AVAILABLE]              L3: 1 of 2
```

ABSTRACT:
The invention relates to improved ifosfamide preparations which are distinguished in that as primary auxiliary a polysaccharide, in general a glycan, preferably dextran, starches or cellulose, in particular dextrans

having an MW of 20,000 to 85,000, modified starches such as hydroxyethyl starch and chemically modified celluloses such as hydroxyethylcellulose and sodium carboxymethylcellulose, a glycol ether, preferably polyethylene glycol, in particular polyethylene glycols having a molecular weight of 600 to 6000 or an amino acid, preferably alanine, leucine or glutamic acid, is added to them.
The improved ifosfamide preparation can also contain as an auxiliary a pharmaceutically customary buffer, for example acetate, citrate or tris buffer, preferably phosphate buffer.
In addition, improved ifosfamide preparations are obtained by addition of NaHCO.sub.3.
The ifosfamide preparations according to the invention can comprise one or a combination of several auxiliaries. Mesna can be added to the formulation as a uroprotector.

US PAT NO: 5,446,033 [IMAGE AVAILABLE] L3: 2 of 2
DATE ISSUED: Aug. 29, 1995
TITLE: Stabilized hexadecylphosphocholine solutions in glycerol alkyl ethers
INVENTOR: Jurgen Engel, Alzenau, Federal Republic of Germany
Elisabeth Wolf-Heuss, Mosbach, Federal Republic of Germany
Helmut Orth, Hanau, Federal Republic of Germany
Burkhard Wichert, Bielefeld, Federal Republic of Germany
Dieter Sauerbier, Werther, Federal Republic of Germany
ASSIGNEE: Asta Medica AG, Federal Republic of Germany (foreign corp.)
APPL-NO: 08/137,964
DATE FILED: Oct. 19, 1993
ART-UNIT: 123
PRIM-EXMR: C. Warren Ivy
ASST-EXMR: Evelyn Huang
LEGAL-REP: Cushman Darby & Cushman

US PAT NO: 5,446,033 [IMAGE AVAILABLE] L3: 2 of 2

ABSTRACT:
Solutions of alkylphosphocholines in glycerol alkyl ethers having enhanced storage stability containing a buffer which maintains the pH value to a range between 4 and 6.

=> e sauerbier, deiter/in

E#	FILE	FREQUENCY	TERM
E1	USPAT	36	SAUERBERG, PER/IN
E2	USPAT	5	SAUERBIER, CHARLES E/IN
E3	USPAT	0 -->	SAUERBIER, DEITER/IN
E4	USPAT	13	SAUERBIER, DIETER/IN
E5	USPAT	2	SAUERBIER, HEINZ/IN
E6	USPAT	3	SAUERBIER, MICHAEL/IN
E7	USPAT	2	SAUERBIER, REINER/IN
E8	USPAT	1	SAUERBREI, DARYL J/IN
E9	USPAT	1	SAUERBREY, ARNIM/IN
E10	USPAT	1	SAUERBREY, BIRGIT/IN
E11	USPAT	1	SAUERBREY, CHARLES A/IN
E12	USPAT	2	SAUERBREY, DAVID W/IN

=> s e4

L4 13 "SAUERBIER, DIETER"/IN

=> d cit 1-

1. 5,834,520, Nov. 10, 1998, Container for injectable mesna solutions; Jurgen Engel, et al., 514/706 [IMAGE AVAILABLE]

2. 5,750,131, May 12, 1998, Ifosfamide lyophilizate preparations; Burkhard Wichert, et al., 424/422, 423; 514/54, 57, 59, 60, 110 [IMAGE AVAILABLE]

3. 5,728,738, Mar. 17, 1998, Injectable mesna solutions; Jurgen Engel, et al., 514/706, 709 [IMAGE AVAILABLE]

4. 5,696,172, Dec. 9, 1997, Injectable mesna solutions; Jurgen Engel, et al., 514/706 [IMAGE AVAILABLE]

5. 5,446,033, Aug. 29, 1995, Stabilized hexadecylphosphocholine solutions in glycerol alkyl ethers; Jurgen Engel, et al., 514/77, 723, 769, 784 [IMAGE AVAILABLE]

6. 5,358,718, Oct. 25, 1994, Tablet containing mesna as active substance and method of making same; **Dieter Sauerbier**, et al., 424/466, 464, 465, 474, 489; 514/772.3, 774, 777, 778, 781 [IMAGE AVAILABLE]

7. 5,262,169, Nov. 16, 1993, Tablets and granulates containing mesna as active substance; **Dieter Sauerbier**, et al., 424/465, 464, 469, 470, 474, 475, 489; 514/578, 770, 772.3, 774, 777, 778, 781, 784 [IMAGE AVAILABLE]

8. 5,252,341, Oct. 12, 1993, Tablets and granulates containing mesna as active substance; **Dieter Sauerbier**, et al., 424/489, 458, 464, 465, 470, 490 [IMAGE AVAILABLE]

9. 5,232,919, Aug. 3, 1993, Azelastine embonate and compositions which contain it; Gerhard Scheffler, et al., 514/212, 826; 540/599 [IMAGE AVAILABLE]

10. 5,204,335, Apr. 20, 1993, Ifosfamide lyophilisate and process for its preparation; **Dieter Sauerbier**, et al., 514/105, 79; 544/1; 558/81 [IMAGE AVAILABLE]

11. 5,158,776, Oct. 27, 1992, Solid oral dosage forms of ifosfamide; **Dieter Sauerbier**, et al., 424/451, 458, 463, 474, 482 [IMAGE AVAILABLE]

12. 4,959,215, Sep. 25, 1990, Ifosfamide-mesna lyophilizate and process for its preparation; **Dieter Sauerbier**, et al., 424/422, 423 [IMAGE AVAILABLE]

13. 4,952,575, Aug. 28, 1990, Solutions of oxaphosphorins having improved stability and process for the preparation thereof; **Dieter Sauerbier**, et al., 514/110 [IMAGE AVAILABLE]

=> d ab 2 13

US PAT NO: 5,750,131 [IMAGE AVAILABLE] L4: 2 of 13

ABSTRACT:
The invention relates to improved ifosfamide preparations which are distinguished in that as primary auxiliary a polysaccharide, in general a glycan, preferably dextran, starches or cellulose, in particular dextrans having an MW of 20,000 to 85,000, modified starches such as hydroxyethyl starch and chemically modified celluloses such as hydroxyethylcellulose and sodium carboxymethylcellulose, a glycol ether, preferably polyethylene glycol, in particular polyethylene glycols having a molecular weight of 600 to 6000 or an amino acid, preferably alanine,

leucine or glutamic acid, is added to them.
The improved ifosfamide preparation can also contain as an auxiliary a pharmaceutically customary buffer, for example acetate, citrate or tris buffer, preferably phosphate buffer.
In addition, improved ifosfamide preparations are obtained by addition of NaHCO.sub.3.
The ifosfamide preparations according to the invention can comprise one or a combination of several auxiliaries. Mesna can be added to the formulation as a uroprotector.

US PAT NO: 4,952,575 [IMAGE AVAILABLE] L4: 13 of 13

ABSTRACT:
Solutions comprising oxazaphosphorins having the general formula ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are radicals and at least two of said radicals are 2-chloroethyl and/or 2-mathanesulfonyloxyethyl and the remaining radical is selected from hydrogen, methyl and ethyl; and about 80% to about 100% (v/v) ethanol; wherein the oxazaphosphorin concentration is about 10% to about 70% (w/v); and a process for the preparation thereof.

=> e reissmann, thomas/in

E#	FILE	FREQUENCY	TERM
E1	USPAT	1	REISSMANN, JURGEN/IN
E2	USPAT	4	REISSMANN, KLAUS/IN
E3	USPAT	1 -->	REISSMANN, THOMAS/IN
E4	USPAT	1	REISSMANN, ULRICH/IN
E5	USPAT	1	REISSMANN, ULRIKE/IN
E6	USPAT	1	REISSMANN, WALTER/IN
E7	USPAT	1	REISSMUELLER, KARL H/IN
E8	USPAT	1	REISSMUELLER, KLAUS/IN
E9	USPAT	2	REISSMUELLER, MANFRED W/IN
E10	USPAT	2	REISSMULLER, ANTON/IN
E11	USPAT	1	REISSNER, FRANK/IN
E12	USPAT	1	REISSNER, HERBERT KURT/IN

=> s e3

L5 1 "REISSMANN, THOMAS"/IN

=> d cit ab

1. 5,663,145, Sep. 2, 1997, Products for administering an initial high dose of Cetrorelix and producing a combination package for use when treating diseases; Jurgen Engel, et al., 514/15, 800 [IMAGE AVAILABLE]

US PAT NO: 5,663,145 [IMAGE AVAILABLE] L5: 1 of 1

ABSTRACT:
For application during the treatment of benign and malign tumour diseases, the product according to the invention containing the initial dose of Cetrorelix acetate and one or more maintenance doses of Cetrorelix acetate, Cetrorelix embonate or a slow-release form of Cetrorelix, is used as a combination preparation for treatment to be administered at specific time intervals.

=> d clms

US PAT NO: 5,663,145 [IMAGE AVAILABLE] L5: 1 of 1

CLAIMS:

CLMS(1)

We claim:

1. A kit comprising
(a) an initial dose of an LHRH antagonist suitable for treatment of hormone-dependent conditions, and
(b) at least one maintenance dose of the LHRH antagonist, in an amount which is insufficient for treating the hormone-dependent conditions when administered alone.

CLMS(2)

2. The kit of claim 1, wherein the LHRH antagonist of (b) is in a slow-releasing formulation.

CLMS(3)

3. The kit of claim 1, wherein the LHRH antagonist is Cetrorelix.

CLMS(4)

4. The kit of claim 3, wherein the initial dose of Cetrorelix is between about 1 and about 60 mg.

CLMS(5)

5. The kit of claim 3, wherein the maintenance dose of Cetrorelix is between about 0.1 and about 60 mg.

CLMS(6)

6. The kit of claim 3, wherein the maintenance dose of Cetrorelix consists of a slow-releasing formulation.

CLMS(7)

7. A method of treating a hormone-dependent condition which comprises the steps of
(a) administering an initial dose of an LHRH antagonist to a person having a hormone-dependent condition, and
(b) then administering to that person a maintenance dose of an LHRH antagonist in an amount which is insufficient for treating the hormone-dependent conditions when administered alone.

CLMS(8)

8. The method of claim 7, wherein the maintenance dose of the LHRH antagonist is a slow-releasing formulation.

CLMS(9)

9. The method of claim 7, wherein the LHRH antagonist is Cetrorelix.

CLMS(10)

10. The method of claim 7, wherein Cetrorelix of the maintenance dose consists of a slow-releasing formulation.

CLMS(11)

11. The method of claim 9, wherein the initial dose of Cetrorelix is between about 1 and about 60 mg, and the maintenance dose of Cetrorelix is between about 0.1 and about 30 mg.

CLMS(12)

12. The method of claim 11, wherein the Cetrorelix of the maintenance dose consists of a slow-releasing formulation.

CLMS(13)

13. The method of claim 7, wherein the hormone-dependent condition is prostate cancer.

CLMS(14)

14. The method of claim 7, wherein the hormone-dependent condition is endometrial hyperplasia.

CLMS(15)

15. The method of claim 7, wherein the hormone-dependent condition is benign prostate hypertrophy.

CLMS(16)

16. The method of claim 7, wherein the hormone-dependent condition is mammary carcinoma.

CLMS(17)

17. The method of claim 7, wherein the hormone-dependent condition is ovarian carcinoma.

CLMS(18)

18. The method of claim 7, wherein the hormone-dependent condition is uterine fibroma.

CLMS(19)

19. The method of claim 7, wherein the hormone-dependent condition is pubertas praecox.

CLMS(20)

20. The method of claim 7, wherein the hormone-dependent condition is pituitary adenomas.

CLMS(21)

21. A method for decreasing male fertility comprising the steps of
(a) administering to a male an initial dose of an LHRH antagonist, and
(b) then administering to that male a maintenance dose of an LHRH antagonist in an amount which is insufficient for decreasing male fertility when administered alone.

CLMS(22)

22. The method of claim 21, wherein the LHRH antagonist is Cetrorelix.

CLMS(23)

23. The method of claim 21, wherein the Cetrorelix of the maintenance dose consists of a slow-releasing formulation.

CLMS(24)

24. The method of claim 22, wherein the initial dose of Cetrorelix is between about 1 and 60 mg, and the maintenance dose of Cetrorelix is between about 0.1 and 30 mg.

CLMS(25)

25. The method of claim 24, wherein the Cetrorelix of the maintenance dose comprises Cetrorelix pamoate or Cetrorelix acetate in a slow-releasing form.

=> s lyophilisat? and cetrorelix

```
          1377 LYOPHILISAT?
             9 CETRORELIX
L6           1 LYOPHILISAT? AND CETRORELIX
```

=> d cit ab

1. 5,663,145, Sep. 2, 1997, Products for administering an initial high dose of **Cetrorelix** and producing a combination package for use when treating diseases; Jurgen Engel, et al., 514/15, 800 [IMAGE AVAILABLE]

US PAT NO: 5,663,145 [IMAGE AVAILABLE] L6: 1 of 1

ABSTRACT:
For application during the treatment of benign and malign tumour diseases, the product according to the invention containing the initial dose of **Cetrorelix** acetate and one or more maintenance doses of **Cetrorelix** acetate, **Cetrorelix** embonate or a slow-release form of **Cetrorelix**, is used as a combination preparation for treatment to be administered at specific time intervals.